scispace - formally typeset
M

Melissa Heightman

Researcher at University College London Hospitals NHS Foundation Trust

Publications -  35
Citations -  1374

Melissa Heightman is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 8 publications receiving 262 citations.

Papers
More filters
Journal ArticleDOI

'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19.

TL;DR: Systematic follow-up after hospitalisation with COVID-19 identifies the trajectory of physical and psychological symptom burden, recovery of blood biomarkers and imaging which could be used to inform the need for rehabilitation and/or further investigation.
Journal ArticleDOI

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.

Rachael A. Evans, +780 more
TL;DR: In this paper, the effects of COVID-19-related hospitalisation on health and employment, to identify factors associated with recovery, and to describe recovery phenotypes were determined.
Journal ArticleDOI

Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study.

TL;DR: In this paper, the authors assessed medium-term organ impairment in symptomatic individuals following recovery from acute SARS-CoV-2 infection and age-matched healthy controls, and found that 60% of individuals had 10 or more symptoms and 60% had severe post-COVID-19 syndrome.
Journal ArticleDOI

Adeno-associated virus 2 infection in children with non-A–E hepatitis

Antonia Ho, +477 more
- 19 Jul 2022 - 
TL;DR: A detailed case-control investigation and finding an association between adeno-associated virus 2 (AAV2) infection and host genetics in disease susceptibility was carried out in this paper , where they detected recent infection with AAV2 in plasma and liver samples in 26 out of 32 (81%) cases of hepatitis compared with 5 out of 74 (7%) of samples from unaffected individuals.